Provider of nucleic acid-based drugs for the treatment of solid tumor cancers. It offers a proprietary antisense oligonucleotide that targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. The Company currently has multiple investigational drug candidates in its pipeline targeting various solid tumor cancer indications. Founded in 2008, headquartered in Santiago, Chile. The company has raised $16. The company operates in Life Sciences > Genomics, Life Sciences > Gene Therapy, High Tech > Nanotechnology, Life Sciences > Oncology. Its business models include Nanotechnology > Nanotools > Genomics > RNA Sequencing, Oncology > Drugs > Diversified, Genomics > Enabling Technologies > Technology Platforms > RNA interference. Founded in 2008. Headquartered in Chile, Santiago. The company has raised funding at the Series B stage. Backed by investors including Aurus, Austral Capital, Prisma Group.
Andes Biotechnologies
Series BProvider of nucleic acid-based drugs for the treatment of solid tumor cancers. It offers a proprietary antisense oligonucleotide that targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. The Company currently has multiple investigational drug candidates in its pipeline targeting various solid tumor cancer indications. Founded in 2008,…
About
Business model
Nanotechnology > Nanotools > Genomics > RNA Sequencing,
Oncology > Drugs > Diversified,
Genomics > Enabling Technologies > Technology Platforms > RNA interference
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.
Similar startups
Raising like Andes Biotechnologies?
Analyze your pitch deck before your next raise.
Analyze My Deck →